The subscription based website, Law360, is reporting that GlaxoSmithKline, along with Teva Pharmaceutical Industries Ltd, have both been named in an antitrust class action lawsuit. Both have been accused of conspiring to keep a generic epilepsy drug off the market in order to maximize profits.
The complaint has been brought by LOUISIANA WHOLESALE DRUG CO., INC., [LWD] on behalf of itself and all others similarly situated:
The 41 page document reveals that the case is brought on behalf of LWD and a class of all other persons or entities in the United States who directly purchased Lamictal brand lamotrigine tablets (“Lamictal Tablets”) from GSK and/or a generic version of Lamictal Tablets from Teva at any time during the Class Period of February 17, 2008 until the effects of Defendants’ conduct ceases (the “Class”)
Law360 writes:
Louisiana Wholesale Drug Co. Inc. filed the suit on behalf of all those who purchased Lamictal-brand lamotrigine tablets since February 2008, alleging that Teva put the brakes on a patent challenge to Lamictal in 2005 in order to strike a deal with GSK that would benefit both companies while hurting consumers.
The subsequent settlement and license agreement allowed Teva to sell limited amounts of a generic version of a Lamictal chewable product in June 2005 but kept Teva from selling the more lucrative Lamictal tablets until July 2008, six months before GSK's patent on the drug expired, according to the complaint.
Surely not?
Arise Sir Witty - time to sort out the mess left behind by old JP.
Fid
ORDER THE PAPERBACK 'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman US and CANADA HERE OR UK HERE
AUSTRALIAN ORDERS HERE
No comments: